FindTrial
Sign In

TO ASSESS THE EFFECTS OF HYALURONIDASE WHEN USED AS WITH 0.25% BUPIVACAINE IN BRACHIAL PLEXUX BLOCK FOR ORTHOPAEDIC SURGERIES.

A COMPARATIVE STUDY OF HYALURONIDASE AGAINST NS WHEN USED AS ADJUVANT TO 0.25% BUPIVACAINE IN SUPRACLAVICULAR APPROACH BRACHIAL PLEXUS BLOCK IN ORTHOPAEDIC SURGERIES.

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/09/057190
Enrollment
48
Registered
2023-09-01
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: S629- Unspecified fracture of wrist andhand

Interventions

Intervention1: SUPRACLAVICULAR APPROACH BRACHIAL PLEXUS BLOCK: USG GUIDED, PERIPHERAL NERVE STIMULATOR CONFIRMATORY SUPRACLAVICULAR APPROACH BRACHIAL PLEXUS BLOCK USING EITHER 0.25% BUPIVACAINE(19.5ML

Sponsors

ESI-PGIMSR,JOKA,KOLKATA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age 18 to 60 years. 2. Schedule for elective surgery of the upper extremities. 3. Informed consent is given by the patients. 4. ASA physical status I & II.

Exclusion criteria

Exclusion criteria: 1. Allergy to injection bupivacaine or hyaluronidase. 2. Severe renal and hepatic disease. 3. Respiratory disease 4. Pulmonary and cardiac disease. 5. Neurologic, psychiatry disease. 6. Neuromuscular disease. 7. Pregnant or lactating women. 8. Morbid obesity. 9. Coagulation disorder cases. 10. Estimated surgical time duration more than 4 hours. 11. Unable to communicate. 12. Failure of peripheral nerve block

Design outcomes

Primary

MeasureTime frame
Reducing the time to reach complete sensory block while using injection hyluronidase as an adjuvants to injetion bupivacaine, so that the turnover time between operations can be reduced.Timepoint: approx one year—

Secondary

MeasureTime frame
a) To compare the safety and to compare the efficacy of hyaluronidase with 0.25% Bupivacaine against normal saline with 0.25% Bupivacaine.Timepoint: approx one year—

Countries

India

Contacts

Public ContactNIYAZUDDIN HUSSAINY

ESI-PGIMSR,ESIC MEDICAL COLLEGE JOKA,KOLKATA

dr.manas.karmakar@esic.nic.in9153131139

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026